The global market for artificial intelligence (AI) in drug discovery is projected to grow significantly in the coming years, with emerging companies adding value and the increasing prevalence of chronic diseases driving demand, although limitations and a shortage of AI workforce may hinder growth.
The use of AI algorithms by insurance companies to assess claims is raising concerns about potential bias and lack of human oversight, leading Pennsylvania legislators to propose legislation that would regulate the use of AI in claims processing.
Kaiser Permanente is using augmented intelligence (AI) to improve patient care, with programs such as the Advanced Alert Monitor (AAM) that identifies high-risk patients, as well as AI systems that declutter physicians' inboxes and analyze medical images for potential risks. These AI-driven applications have proven to be effective in preventing deaths and reducing readmissions, demonstrating the value of integrating AI into healthcare.
Artificial intelligence (AI) has the potential to revolutionize healthcare by improving disease detection and diagnosis, enhancing healthcare systems, and benefiting health care providers, but it also presents challenges that must be addressed, such as developing robust and reliable AI models and ensuring ethical and responsible use.
AI has the potential to revolutionize healthcare by shifting the focus from treating sickness to preventing it, leading to longer and healthier lives, lower healthcare costs, and improved outcomes.
Artificial intelligence (AI) has the potential to greatly improve health care globally by expanding access to health services, according to Google's chief health officer, Karen DeSalvo. Through initiatives such as using AI to monitor search queries for potential self-harm, as well as developing low-cost ultrasound devices and automated screening for tuberculosis, AI can address health-care access gaps and improve patient outcomes.
Artificial intelligence (AI) tools can put human rights at risk, as highlighted by researchers from Amnesty International on the Me, Myself, and AI podcast, who discuss scenarios in which AI is used to track activists and make automated decisions that can lead to discrimination and inequality, emphasizing the need for human intervention and changes in public policy to address these issues.
The authors propose a framework for assessing the potential harm caused by AI systems in order to address concerns about "Killer AI" and ensure responsible integration into society.
The lack of regulation surrounding artificial intelligence in healthcare is a significant threat, according to the World Health Organization's European regional director, who highlights the need for positive regulation to prevent harm while harnessing AI's potential.
Scientists have trained an artificial intelligence (AI) system to create an odor map that visually displays the relationships between different smells and accurately predicts what a new molecule would smell like, with the AI's descriptions outperforming those of human panelists in most cases.
Artificial intelligence (AI) in healthcare must adopt a more holistic approach that includes small data, such as lived experiences and social determinants of health, in order to address health disparities and biases in treatment plans.
Researchers at OSF HealthCare in Illinois have developed an artificial intelligence (AI) model that predicts a patient's risk of death within five to 90 days after admission to the hospital, with the aim of facilitating important end-of-life discussions between clinicians and patients. The AI model, tested on a dataset of over 75,000 patients, showed that those identified as more likely to die during their hospital stay had a mortality rate three times higher than the average. The model provides clinicians with a probability and an explanation of the patient's increased risk of death, prompting crucial conversations about end-of-life care.
The Department of Homeland Security (DHS) has announced new policies for the use of artificial intelligence (AI) to secure the border, prioritizing rigorous testing, safeguarding privacy, and avoiding biases, while also allowing Americans to decline the use of facial recognition technology in certain situations.
The restaurant industry is increasingly incorporating artificial intelligence (AI) to reduce costs, enhance productivity, and improve customer experience.
Major drugmakers are using artificial intelligence (AI) to accelerate drug development by quickly finding patients for clinical trials and reducing the number of participants needed, potentially saving millions of dollars. AI is increasingly playing a substantial role in human drug trials, with companies such as Amgen, Bayer, and Novartis using AI tools to scan vast amounts of medical data and identify suitable trial patients, significantly reducing the time and cost of recruitment. The use of AI in drug development is on the rise, with the US FDA receiving over 300 applications that incorporate AI or machine learning in drug development from 2016 through 2022.
